Role of Antigen-specific Regulatory CD4+CD25+ T Cells in Tolerance Induction After Neonatal IP Administration of AAV-hF.IX

Overview

Journal Gene Ther

Date 2013 Jun 14

PMID 23759700

Citations 10

Authors

Y Shi

R Falahati

J Zhang

L Flebbe-Rehwaldt

K M L Gaensler

Affiliations

Soon will be listed here.

Abstract

Neonatal AAV8-mediated Factor IX (F.IX) gene delivery was applied as a model for exploring mechanisms of tolerance induction during immune ontogeny. Intraperitoneal delivery of AAV8/ Factor IX (hF.IX) during weeks 1-4 of life, over a 20-fold dose range, directed stable hF.IX expression, correction of coagulopathy in F.IX-null hemophilia B mice, and induction of tolerance to hF.IX; however, only primary injection at 1-2 days of life enabled increasing AAV8-mediated hF.IX expression after re-administration, due to the absence of anti-viral capsid antibodies. Adoptive splenocyte transfer from tolerized mice demonstrated induction of CD4(+)CD25(+) T regulatory (T(reg)) populations that specifically suppressed anti-hF.IX antibody responses, but not responses to third party antigen. Induction of hF.IX antibodies was only observed in tolerized mice after in vivo CD4(+)CD25(+) cell depletion and hF.IX challenge. Thus, primary injection of AAV during a critical period in the first week of life does not elicit antiviral responses, enabling re-administration of AAV and augmentation of hF.IX levels. Expansion of hF.IX-specific CD4(+)CD25(+) T(regs) has a major role in tolerance induction early in immune ontogeny. Neonatal gene transfer provides a useful approach for defining the ontogeny of immune responses and may suggest approaches for inducing tolerance in the context of genetic therapies.

Citing Articles

Production of lentiviral vectors using novel, enzymatically produced, linear DNA.

Karda R, Counsell J, Karbowniczek K, Caproni L, Tite J, Waddington S Gene Ther. 2019; 26(3-4):86-92.

PMID: 30643205 PMC: 6760675. DOI: 10.1038/s41434-018-0056-1.

Argininosuccinic aciduria fosters neuronal nitrosative stress reversed by Asl gene transfer.

Baruteau J, Perocheau D, Hanley J, Lorvellec M, Rocha-Ferreira E, Karda R Nat Commun. 2018; 9(1):3505.

PMID: 30158522 PMC: 6115417. DOI: 10.1038/s41467-018-05972-1.

Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes.

Iizuka S, Sakurai F, Tachibana M, Ohashi K, Mizuguchi H Mol Ther Methods Clin Dev. 2017; 6:183-193.

PMID: 28828393 PMC: 5552065. DOI: 10.1016/j.omtm.2017.07.001.

Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.

Baruteau J, Waddington S, Alexander I, Gissen P J Inherit Metab Dis. 2017; 40(4):497-517.

PMID: 28567541 PMC: 5500673. DOI: 10.1007/s10545-017-0053-3.

Induction of Immune Tolerance to Foreign Protein via Adeno-Associated Viral Vector Gene Transfer in Mid-Gestation Fetal Sheep.

Davey M, Riley J, Andrews A, Tyminski A, Limberis M, Pogoriler J PLoS One. 2017; 12(1):e0171132.

PMID: 28141818 PMC: 5283730. DOI: 10.1371/journal.pone.0171132.

References

Herzog R, Yang E, Couto L, Hagstrom J, Elwell D, Fields P . Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999; 5(1):56-63. DOI: 10.1038/4743. View

Stilwell J, Samulski R . Adeno-associated virus vectors for therapeutic gene transfer. Biotechniques. 2003; 34(1):148-50, 152, 154 passim. DOI: 10.2144/03341dd01. View

Wang L, Zoppe M, Hackeng T, Griffin J, Lee K, Verma I . A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A. 1997; 94(21):11563-6. PMC: 23538. DOI: 10.1073/pnas.94.21.11563. View

Finn J, Hui D, Downey H, Dunn D, Pien G, Mingozzi F . Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol Ther. 2009; 18(1):135-42. PMC: 2839204. DOI: 10.1038/mt.2009.257. View

Kelly M, Bharadwaj A, Tacke F, Chao H . Regulatory T cells and immune tolerance to coagulation factor IX in the context of intramuscular AAV1 gene transfer. Mol Ther. 2009; 18(2):361-9. PMC: 2839290. DOI: 10.1038/mt.2009.269. View

Nayak S, Herzog R . Progress and prospects: immune responses to viral vectors. Gene Ther. 2009; 17(3):295-304. PMC: 3044498. DOI: 10.1038/gt.2009.148. View

Garza K, Agersborg S, Baker E, Tung K . Persistence of physiological self antigen is required for the regulation of self tolerance. J Immunol. 2001; 164(8):3982-9. DOI: 10.4049/jimmunol.164.8.3982. View

Kay M, Manno C, Ragni M, Larson P, Couto L, McClelland A . Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000; 24(3):257-61. DOI: 10.1038/73464. View

Cohn E, Zhuo J, Kelly M, Chao H . Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer. J Thromb Haemost. 2007; 5(6):1227-36. DOI: 10.1111/j.1538-7836.2007.02522.x. View

10.

Chang A, Stephan M, Lisowski L, Sadelain M . Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice. Mol Ther. 2008; 16(10):1745-52. PMC: 2658893. DOI: 10.1038/mt.2008.161. View

11.

Lipshutz G, Gruber C, Cao Y , Hardy J, Contag C, Gaensler K . In utero delivery of adeno-associated viral vectors: intraperitoneal gene transfer produces long-term expression. Mol Ther. 2001; 3(3):284-92. DOI: 10.1006/mthe.2001.0267. View

12.

Waddington S, Nivsarkar M, Mistry A, Buckley S, Kemball-Cook G, Mosley K . Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood. 2004; 104(9):2714-21. DOI: 10.1182/blood-2004-02-0627. View

13.

Chatenoud L, Salomon B, Bluestone J . Suppressor T cells--they're back and critical for regulation of autoimmunity!. Immunol Rev. 2001; 182:149-63. DOI: 10.1034/j.1600-065x.2001.1820112.x. View

14.

Kelly M, Zhuo J, Bharadwaj A, Chao H . Induction of immune tolerance to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependent. Mol Ther. 2009; 17(5):857-63. PMC: 2835131. DOI: 10.1038/mt.2009.25. View

15.

Kung S, Hagstrom J, Cass D, Tai S, Lin H, Stafford D . Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood. 1998; 91(3):784-90. View

16.

Ogura T, Mizukami H, Mimuro J, Madoiwa S, Okada T, Matsushita T . Utility of intraperitoneal administration as a route of AAV serotype 5 vector-mediated neonatal gene transfer. J Gene Med. 2006; 8(8):990-7. DOI: 10.1002/jgm.916. View

17.

Herzog R, High K . Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy. Thromb Haemost. 1999; 82(2):540-6. View

18.

Grimm D, Zhou S, Nakai H, Thomas C, Storm T, Fuess S . Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood. 2003; 102(7):2412-9. DOI: 10.1182/blood-2003-02-0495. View

19.

Zhang J, Xu L, Haskins M, Ponder K . Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs. Blood. 2003; 103(1):143-51. DOI: 10.1182/blood-2003-06-2181. View

20.

Xu L, Gao C, Sands M, Cai S, Nichols T, Bellinger D . Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood. 2003; 101(10):3924-32. DOI: 10.1182/blood-2002-10-3050. View